Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RYZ401 · 1 trial · 9 indications
| Name | Type | Description |
|---|---|---|
| RYZ401 | DRUG | Ac-225 |
RYZ401 is an investigational small molecule being developed for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET), a type of solid tumor that expresses somatostatin receptors. It is currently in Phase 1 clinical development and has not been approved by the FDA.
RYZ401 targets PRMT5, a protein that plays a role in cellular processes. By targeting PRMT5, RYZ401 is being studied for its potential effects in treating gastroenteropancreatic neuroendocrine tumors (GEP-NET) and other solid tumors that express somatostatin receptors.
RYZ401 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is currently conducting clinical trials to evaluate the safety and efficacy of RYZ401 in patients with solid tumors expressing somatostatin receptors.
RYZ401 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to study the drug in subjects with solid tumors that express somatostatin receptors.
RYZ401 is being studied in a Phase 1 clinical trial with the identifier NCT07165132. The trial, titled 'Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs,' is not yet recruiting and aims to enroll 104 participants with conditions including GEP-NET and other neuroendocrine tumors.